Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 489853, 8 pages
http://dx.doi.org/10.1155/2012/489853
Review Article

Receptor Antagonism and Dyskinesia in Parkinson’s Disease

1Department of Biomedical Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy
2CNR Institute of Neuroscience, 09042 Cagliari, Italy
3Interdepartmental Research Center for Parkinson’s Disease, National Neurological Institute C. Mondino, 27100 Pavia, Italy
4Department of Neurology, University of South Florida, Tampa, FL 33613, USA

Received 21 February 2012; Accepted 26 April 2012

Academic Editor: Anna Rosa Carta

Copyright © 2012 Micaela Morelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. S. Fink, D. R. Weaver, S. A. Rivkees et al., “Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum,” Molecular Brain Research, vol. 14, no. 3, pp. 186–195, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. S. N. Schiffmann, F. Libert, G. Vassart, and J. J. Vanderhaeghen, “Distribution of adenosine A2 receptor mRNA in the human brain,” Neuroscience Letters, vol. 130, no. 2, pp. 177–181, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Canals, D. Marcellino, F. Fanelli et al., “Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer,” Journal of Biological Chemistry, vol. 278, no. 47, pp. 46741–46749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fuxe, L. F. Agnati, K. Jacobsen et al., “Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease,” Neurology, vol. 61, no. 11, pp. S19–S23, 2003. View at Google Scholar · View at Scopus
  5. J. Hillion, M. Canals, M. Torvinen et al., “Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors,” Journal of Biological Chemistry, vol. 277, no. 20, pp. 18091–18097, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Short, C. Ledent, E. Borrelli, J. Drago, and A. J. Lawrence, “Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice,” Neuroscience, vol. 139, no. 2, pp. 661–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Morelli, T. Di Paolo, J. Wardas, F. Calon, D. Xiao, and M. A. Schwarzschild, “Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications,” Progress in Neurobiology, vol. 83, no. 5, pp. 293–309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Pinna, S. Pontis, F. Borsini, and M. Morelli, “Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease,” Synapse, vol. 61, no. 8, pp. 606–614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. R. A. Hauser and M. A. Schwarzschild, “Adenosine A2A receptor antagonists for Parkinson's disease rationale, therapeutic potential and clinical experience,” Drugs and Aging, vol. 22, no. 6, pp. 471–482, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. H. Adair, “Growth regulation of the vascular system: an emerging role for adenosine,” American Journal of Physiology, vol. 289, no. 2, pp. R283–R296, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Lukashev, A. Ohta, S. Apasov, J. F. Chen, and M. Sitkovsky, “Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo,” Journal of Immunology, vol. 173, no. 1, pp. 21–24, 2004. View at Google Scholar · View at Scopus
  12. F. Calon, M. Dridi, O. Hornykiewicz, P. J. Bédard, A. H. Rajput, and T. Di Paolo, “Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias,” Brain, vol. 127, no. 5, pp. 1075–1084, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Pinna, C. Corsi, A. R. Carta, V. Valentini, F. Pedata, and M. Morelli, “Modification of adenosine extracellular levels and adenosine A2A receptor mRNA by dopamine denervation,” European Journal of Pharmacology, vol. 446, no. 1-3, pp. 75–82, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tomiyama, T. Kimura, T. Maeda, H. Tanaka, K. Kannari, and M. A. Baba, “Upregulation of Striatal Adenosine A2A Receptor mRNA in 6-Hydroxydopamine-Lesioned Rats Intermittently Treated with L-DOPA,” Synapse, vol. 52, no. 3, pp. 218–222, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Brooks, S. Papapetropoulos, F. Vandenhende et al., “An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers,” Clinical Neuropharmacology, vol. 33, no. 2, pp. 55–60, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mishina, K. Ishiwata, M. Naganawa et al., “Adenosine A2A receptors measured with [11C]TMSX pet in the striata of parkinson's disease patients,” PLoS ONE, vol. 6, no. 2, Article ID e17338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Pinna, S. Fenu, and M. Morelli, “Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatment in 6-hydroxydopamine-lesioned rats,” Synapse, vol. 39, no. 3, pp. 233–238, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Henry, A. R. Crossman, and J. M. Brotchie, “Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease,” Experimental Neurology, vol. 151, no. 2, pp. 334–342, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Pinna, S. Pontis, and M. Morelli, “Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment,” Behavioural Brain Research, vol. 171, no. 1, pp. 175–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Tronci, N. Simola, F. Borsini et al., “Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats,” European Journal of Pharmacology, vol. 566, no. 1–3, pp. 94–102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Lundblad, E. Vaudano, and M. A. Cenci, “Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia,” Journal of Neurochemistry, vol. 84, no. 6, pp. 1398–1410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Grondin, P. J. Bédard, A. H. Tahar, L. Grégoire, A. Mori, and H. Kase, “Antiparkinsonian effect of a new selective adenosine A(2A) receptor antagonist in MPTP-treated monkeys,” Neurology, vol. 52, no. 8, pp. 1673–1677, 1999. View at Google Scholar · View at Scopus
  23. R. A. Hodgson, P. J. Bedard, G. B. Varty et al., “Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders,” Experimental Neurology, vol. 225, no. 2, pp. 384–390, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Kanda, M. J. Jackson, L. A. Smith et al., “Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys,” Experimental Neurology, vol. 162, no. 2, pp. 321–327, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Bibbiani, J. D. Oh, J. P. Petzer et al., “A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease,” Experimental Neurology, vol. 184, no. 1, pp. 285–294, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. C. R. Gerfen, T. M. Engber, L. C. Mahan et al., “D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons,” Science, vol. 250, no. 4986, pp. 1429–1432, 1990. View at Google Scholar · View at Scopus
  27. A. R. Carta, A. Pinna, O. Cauli, and M. Morelli, “Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats,” Synapse, vol. 44, no. 3, pp. 166–174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Y. Zeng, R. K. B. Pearce, G. M. MacKenzie, and P. Jenner, “Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA,” European Journal of Neuroscience, vol. 12, no. 3, pp. 1096–1104, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Ferré, B. B. Fredholm, M. Morelli, P. Popoli, and K. Fuxe, “Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia,” Trends in Neurosciences, vol. 20, no. 10, pp. 482–487, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. D. L. Rosin, B. D. Hettinger, A. Lee, and J. Linden, “Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function,” Neurology, vol. 61, no. 11, pp. S12–S18, 2003. View at Google Scholar · View at Scopus
  31. F. Gardoni, V. Ghiglieri, M. D. Luca, and P. Calabresi, “Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease,” Progress in Brain Research, vol. 183, no. C, pp. 169–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. T. N. Chase, F. Bibbiani, W. Bara-Jimenez, T. Dimitrova, and J. D. Oh-Lee, “Translating A2A antagonist KW6002 from animal models to parkinsonian patients,” Neurology, vol. 61, no. 11, pp. S107–S111, 2003. View at Google Scholar · View at Scopus
  33. K. Wirkner, Z. Gerevich, T. Krause et al., “Adenosine A2A receptor-induced inhibition of NMDA and GABA A receptor-mediated synaptic currents in a subpopulation of rat striatal neurons,” Neuropharmacology, vol. 46, no. 7, pp. 994–1007, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Calabresi, F. Galletti, E. Saggese, V. Ghiglieri, and B. Picconi, “Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits,” Parkinsonism and Related Disorders, vol. 13, no. 3, pp. S259–S262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. E. Kelley, M. E. Andrzejewski, A. E. Baldwin, P. J. Hernandez, and W. E. Pratt, “Glutamate-mediated plasticity in corticostriatal networks: role in adaptive motor learning,” Annals of the New York Academy of Sciences, vol. 1003, pp. 159–168, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Ferré, M. Karcz-Kubicha, B. T. Hope et al., “Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 18, pp. 11940–11945, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Kachroo, L. R. Orlando, D. K. Grandy, J. F. Chen, A. B. Young, and M. A. Schwarzschild, “Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice,” Journal of Neuroscience, vol. 25, no. 45, pp. 10414–10419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Lopez, N. Turle-Lorenzo, T. H. Johnston et al., “Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats,” Neuropharmacology, vol. 55, no. 4, pp. 483–490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. T. H. Johnston, S. H. Fox, M. J. McIldowie, M. J. Piggott, and J. M. Brotchie, “Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 865–873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Carriba, O. Ortiz, K. Patkar et al., “Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids,” Neuropsychopharmacology, vol. 32, no. 11, pp. 2249–2259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Ferré, C. Lluís, Z. Justinova et al., “Adenosine-cannabinoid receptor interactions. Implications for striatal function,” British Journal of Pharmacology, vol. 160, no. 3, pp. 443–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Łukasiewicz, E. Błasiak, A. Faron-Górecka et al., “Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane,” Pharmacological Reports, vol. 59, no. 4, pp. 379–392, 2007. View at Google Scholar · View at Scopus
  43. F. Ciruela, V. Casadó, R. J. Rodrigues et al., “Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers,” Journal of Neuroscience, vol. 26, no. 7, pp. 2080–2087, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Popoli, C. Frank, M. T. Tebano et al., “Modulation of glutamate release and excitotoxicity by adenosine A2A receptors,” Neurology, vol. 61, no. 11, pp. S69–S71, 2003. View at Google Scholar · View at Scopus
  45. M. Mishina, K. Ishiwata, Y. Kimura et al., “Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET,” Synapse, vol. 61, no. 9, pp. 778–784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. F. Ramlackhansingh, S. K. Bose, I. Ahmed, F. E. Turkheimer, N. Pavese, and D. J. Brooks, “Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease,” Neurology, vol. 76, no. 21, pp. 1811–1816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. K. J. Black, J. M. Koller, M. C. Campbell, D. A. Gusnard, and S. I. Bandak, “Quantification of indirect pathway inhibition by the adenosine A2A antagonist SYN115 in Parkinson disease,” Journal of Neuroscience, vol. 30, no. 48, pp. 16284–16292, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Varani, F. Vincenzi, A. Tosi et al., “A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson's disease,” FASEB Journal, vol. 24, no. 2, pp. 587–598, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. W. Bara-Jimenez, A. Sherzai, T. Dimitrova et al., “Adenosine A2A receptor antagonist treatment of Parkinson's disease,” Neurology, vol. 61, no. 3, pp. 293–296, 2003. View at Google Scholar · View at Scopus
  50. R. A. Hauser, J. P. Hubble, and D. D. Truong, “Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD,” Neurology, vol. 61, no. 3, pp. 297–303, 2003. View at Google Scholar · View at Scopus
  51. P. A. LeWitt, M. Guttman, J. W. Tetrud et al., “Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005),” Annals of Neurology, vol. 63, no. 3, pp. 295–302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Stacy, D. Silver, T. Mendis et al., “A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease,” Neurology, vol. 70, no. 23, pp. 2233–2240, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. A. Hauser, L. M. Shulman, J. M. Trugman et al., “Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations,” Movement Disorders, vol. 23, no. 15, pp. 2177–2185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Mizuno, K. Hasegawa, T. Kondo et al., “Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study,” Movement Disorders, vol. 25, no. 10, pp. 1437–1443, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. W. Knebel, N. Rao, T. Uchimura et al., “Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with parkinson's disease,” Journal of Clinical Pharmacology, vol. 51, no. 1, pp. 40–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. R. A. Hauser, M. Cantillon, E. Pourcher et al., “Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial,” The Lancet Neurology, vol. 10, no. 3, pp. 221–229, 2011. View at Publisher · View at Google Scholar · View at Scopus